We read with great interest the study by Van der Voort et al ,1 which compared rectal versus colonic submucosal cancer rates ...

Correspondence to Dr Melina Arnold, Section of Cancer Surveillance, International Agency for Research on Cancer, 150 Cours Albert Thomas, Lyon 69008, France; arnoldm{at}fellows.iarc.fr Objective The ...

The 2022 UK-wide acute upper gastrointestinal bleeding (AUGIB) audit by Nigam and colleagues is a landmark. With ...

2 Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan 3 Department of Internal Medicine, GI Unit, Massachusetts General Hospital, Boston, Massachusetts, USA 4 ...

Objective Data from clinical research suggest that certain probiotic bacterial strains have the potential to modulate colonic inflammation. Nonetheless, these data differ between studies due to the ...

Correspondence to Dr Gengqing Song, Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH 44109, USA; songgavin2010{at}gmail.com ...

Correspondence to Professor Shiv Kumar Sarin, Hepatology, Institute of Liver and Biliary Sciences, New Delhi, Delhi 110070, India; shivsarin{at}gmail.com Objectives Beta-blockers and endoscopic ...

Background—Peripheral arthropathy is a well-recognised complication of inflammatory bowel disease (IBD). Little is known of its natural history, but a variety of joint involvement has been described, ...

Background Irritable bowel syndrome with diarrhoea (IBS-D) is particularly debilitating due to urgency and episodic incontinence. Some 5-hydroxytryptamine 3 (5-HT3) receptor antagonists (5-HT3RAs) ...

Correspondence to Dr Ikuo Hirano, Professor of Medicine, Division of Gastroenterology, Northwestern University Feinberg School of Medicine, 676 North Saint Clair, Suite 1400, Chicago, IL 60611, USA; i ...

Background Gut microbial metabolites are recognised as critical effector molecules that influence the development of colorectal cancer (CRC). Peptidoglycan fragments (PGFs) produced by microbiota play ...

Objective There are numerous biological therapies and small molecules licensed for luminal Crohn’s disease (CD), but these are often studied in placebo-controlled trials, meaning relative efficacy is ...